30
Participants
Start Date
September 30, 2010
Primary Completion Date
October 31, 2012
Study Completion Date
October 31, 2012
IW001
IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
Medical University of South Carolina, Charleston
University of Miami, Miami
University of Alabama at Birmingham, Birmingham
Vanderbilt University, Nashville
University of Louisville, Louisville
Ohio State University, Columbus
IUPUI, Indianapolis
University of Michigan, Ann Arbor
University of Chicago, Chicago
Newark Beth Israel Hospital, Newark
University of Vermont, Burlington
Lead Sponsor
ImmuneWorks
INDUSTRY